Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children

DSpace/Manakin Repository

Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children

Show simple item record

dc.contributor.author Bridges, Carolyn Buxton
dc.contributor.author Uyeki, Timothy M.
dc.contributor.author Meltzer, Martin I.
dc.contributor.author Molinari, Noelle-Angelique M.
dc.contributor.author Fukuda, Keiji
dc.contributor.author Prosser, Lisa Alison
dc.contributor.author Schwartz, Benjamin
dc.contributor.author Thompson, William W.
dc.contributor.author Lieu, Tracy Ann
dc.contributor.author Hinrichsen, Virginia L.
dc.date.accessioned 2012-12-07T22:19:17Z
dc.date.issued 2006
dc.identifier.citation Prosser, Lisa Alison, Carolyn Buxton Bridges, Timothy M. Uyeki, Virginia L. Hinrichsen, Martin I. Meltzer, Noelle-Angelique M. Molinari, Benjamin Schwartz, William W. Thompson, Keiji Fukuda, and Tracy Ann Lieu. 2006. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerging Infectious Diseases 12(10): 1548-1558. en_US
dc.identifier.issn 1080-6040 en_US
dc.identifier.issn 1080-6059 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:10021413
dc.description.abstract We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6–23 months to $119,000 per QALY saved for children ages 12–17 years. For children at high risk (preexisting medical conditions) ages 6–35 months, vaccination with IIV was cost saving. For children at high risk ages 3–17 years, vaccination cost $1,000–$10,000 per QALY. Among children not at high risk ages 5–17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6–23 months plus all other children at high risk. en_US
dc.language.iso en_US en_US
dc.publisher U.S. National Center for Infectious Diseases en_US
dc.relation.isversionof doi:10.3201/eid1210.051015 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290928 en_US
dash.license LAA
dc.title Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Emerging Infectious Diseases en_US
dash.depositing.author Prosser, Lisa Alison
dc.date.available 2012-12-07T22:19:17Z

Files in this item

Files Size Format View
3290928.pdf 461.0Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters